covid-19 virus

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | February 17, 2021 | News story | Research and Development |  COVID-19, COVID-19 vaccine, Vaccine, World Health Organisation, covid-19 roundup 

The past week has continued to see positive COVID-19 vaccine news; a WHO panel approved the Oxford-AstraZeneca vaccine for all adults, the Pfizer-BioNTech shot has been proven 94% effective in a major study of 1.2 million people, and South Korea have ramped up their vaccination programme by ordering doses for 23 million more people.

1. WHO panel recommends AstraZeneca COVID-19 vaccine for over-65s – Published 11/02/2021

Scientists advising the WHO have recommended the use of the Oxford-AstraZeneca COVID-19 vaccine in all adults, including those aged over 65.

Advertisement

2. AstraZeneca COVID-19 vaccine still restricted, despite WHO assurances – Published 12/02/21

Several European countries have continued to impose age restrictions on their rollouts of the Oxford University-AstraZeneca vaccine, despite WHO’s repeated assurances that it is safe and effective.

3. Pfizer COVID-19 vaccine proven 94% effective in biggest study yet – Published 15/02/21

The Pfizer-BioNTech COVID-19 vaccine has been proven to be 94% effective, according to the first major study to evaluate the shot’s efficacy.

4. South Korea orders 46 million more Novavax and Pfizer COVID-19 vaccines – Published – 16/02/21

South Korea has arranged deals with Novavax and Pfizer-BioNTech to buy enough COVID-19 vaccines for 23 million more people. 

5. WHO approves two versions of AstraZeneca’s COVID-19 vaccine – Published 16/02/21

The WHO has greenlighted two versions of the Oxford-AstraZeneca COVID-19 vaccine for emergency use, granting them authorisation to be rolled out globally through COVAX.

Related Content

Tridem begins phase Ib trial of Parkinson’s disease vaccine

Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Canada awards CSL Seqirus with influenza pandemic vaccine contract

CSL Seqirus has been awarded a contract committing it to manufacturing and delivering influenza vaccines …

The Gateway to Local Adoption Series

Latest content